AI Article Synopsis

  • Public health interventions need to balance the health of many people with the rights and freedom of individuals.
  • Guidelines for preventing the spread of tuberculosis in communities were created to ensure both community and individual well-being are considered.
  • The National TB Coalition of America used a special method to develop these guidelines, making sure to include ethics and transparency in decision-making.

Article Abstract

Public health interventions often involve explicit tradeoffs in which the health of the many must be weighed against burdens imposed on individuals. We describe development of public health guidelines for respiratory isolation in community settings for persons with tuberculosis. While stopping the spread of disease is a core moral imperative in public health, the duty to prevent disease transmission does not supersede all other considerations. Community wellbeing must be balanced with individual wellbeing, liberty, and social justice. In response to these challenges, the National TB Coalition of America's (NTCA) 2024 Guidelines for persons with tuberculosis in community settings were developed using a modified GRADE approach supported by a complementary, comprehensive, and context-specific ethical framework. By addressing the distinct roles that evidence (subject to uncertainty), values, justificatory conditions, and procedural legitimacy all play in ethical guideline development, we promote rigor and transparency in the integration of ethics in public health guidelines.

Download full-text PDF

Source
http://dx.doi.org/10.1093/infdis/jiae478DOI Listing

Publication Analysis

Top Keywords

public health
20
community settings
12
ethics public
8
guideline development
8
guidelines respiratory
8
respiratory isolation
8
health guidelines
8
persons tuberculosis
8
health
6
public
5

Similar Publications

Background: Pharmacoepidemiologic studies assessing drug effectiveness for Alzheimer's disease and related dementias (ADRD) are increasingly popular given the critical need for effective therapies for ADRD. To meet the urgent need for robust dementia ascertainment from real-world data, we aimed to develop a novel algorithm for identifying incident and prevalent dementia in claims.

Method: We developed algorithm candidates by different timing/frequency of dementia diagnosis/treatment to identify dementia from inpatient/outpatient/prescription claims for 6,515 and 3,997 participants from Visits 5 (2011-2013; mean age 75.

View Article and Find Full Text PDF

Background: Availability of amyloid modifying therapies will dramatically increase the need for disclosure of Alzheimer's disease (AD) related genetic and/or biomarker test results. The 21st Century Cares Act requires the immediate return of most medical test results, including AD biomarkers. A shortage of genetic counselors and dementia specialists already exists, thus driving the need for scalable methods to responsibly communicate test results.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA.

Background: Some types of cancer have been associated with reduced risk of clinical dementia diagnosis. Whether cancer history may be associated with neuropathological features of neurodegeneration or cerebrovascular disease is not well understood. We investigated the relation between cancer diagnosis and brain pathology in a sample of community-based research volunteers enrolled in an Alzheimer's Disease Research Center (ADRC) cohort.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.

Background: The first disease-modifying treatments (DMTs) for Alzheimer's disease (AD) have been approved in the USA, marking profound changes in AD-diagnosis and treatment. This will bring new challenges in terms of clinician-patient communication. We aimed to collect the perspectives of memory clinic professionals regarding the most important topics to address and what (tools) would support professionals and their patients and care partners to engage in a meaningful conversation on whether (or not) to initiate treatment.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

The George Institute for Global Health, University of New South Wales, Imperial College London, Sydney, NSW, Australia.

Background: Recent growth in the functionality and use of technology has prompted an increased interest in the potential for remote or decentralised clinical trials in dementia. There are many potential benefits associated with decentralised medication trials, but the field is currently lacking specific recommendations for their delivery in the dementia field.

Method: A modified Delphi method engaged a panel with substantial expertise in dementia trial design and delivery and backgrounds that included neurology, psychiatry, pharmacology and psychology, to develop recommendations for the conduct of decentralised medication trials in dementia prevention.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!